
Spain set to unveil the potential of the biologisation of medicine and food production
At BioSpain 2023, several panels discussed the Spanish EU Presidency's goal of setting the course for the internationally competitive use of...

VectorY Therapeutics raises €129m in Series A round
EQT Life Sciences and Forbion co-led the €129m Series A financing that will support clinical development of VectorY Therapeutics BVs lead...

New detection method for protein degraders
The research team from MPI of Biochemistry and the University of Waterloo have developed a new way to detect those CRLs in the fleet that are...

Quotient Therapeutics kicks-off with US$50m financing
Flagship has confírmed to invest $50m in Quotient Therapeutics to advance development of a platform, licenced from Wellcome Sanger Institue...

Sanofi licences vaccine against bacterial sepsis
Extraintestinal pathogenic E. coli (ExPEC) is a leading bacterial cause of sepsis, causing approximately 10 million cases of invasive E. coli...

Takeover in ADC space: Abbvie snags ImmunoGen
AbbVie has become the latest big pharma company to target the hot antibody-drug conjugate market, acquiring ImmunoGen and its Elahere ADC for...

Crucible Therapeutics spins out with £5m
Crucible Therapeutics Ltd., the newly launched spinout company from the University of Sheffield, secured the investment of £5m from Northern...